← ANALYST RATINGS · TIPRANKS
Mirum Pharmaceuticals (MIRM): analyst forecast and price target
Analyst consensus
Strong Buy12 Buy0 Hold0 Sell
Ratings of 12 analysts in the last 3 months12-month forecast
Based on 12 price targets given in the last 3 months, the average target is $154, the highest $200, the lowest $130. The average is +92.2% from the last price of $80.14.
Analyst ratings 14
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| James Condulis★★★★★★★★★★#3810 · hits 56% · avg +8.9% | Stifel Nicolaus | $136 → $156+14.7% | Buy | +94.7% | Reiterated | 14.10.26on TipRanks 16:25 | +2.8%next day −1.6% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $92.00 → $86.00−6.5% | Hold | +7.3% | Reiterated | 13.10.26on TipRanks 12:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $89.00 → $86.00−3.4% | Hold | +7.3% | Reiterated | 13.10.26on TipRanks 12:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $88.00 → $86.00−2.3% | Hold | +7.3% | Reiterated | 13.10.26on TipRanks 12:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $91.00 → $86.00−5.5% | Hold | +7.3% | Reiterated | 13.10.26on TipRanks 12:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $96.00 → $90.00−6.2% | Hold | +12.3% | Reiterated | 13.10.26on TipRanks 12:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $92.00 → $85.00−7.6% | Hold | +6.1% | Reiterated | 13.10.26on TipRanks 12:05 | — | |
| Gavin Clark-Gartner★★★★★★★★★★#172 · hits 68% · avg +40.8% | Evercore ISI | $135 → $146+8.1% | Buy | +82.2% | Reiterated | 13.10.26on TipRanks 08:35 | −7.5%next day +1.5% | ↗ |
| Jessica Fye★★★★★★★★★★#1182 · hits 56% · avg +9.4% | J.P. Morgan | — | Buy | — | Reiterated | 12.10.26on TipRanks Oct 13 09:05 | +0.1%next day −7.5% | ↗ |
| Michael Ulz★★★★★★★★★★#6183 · hits 43% · avg +0.9% | Morgan Stanley | $137 → $152+10.9% | Buy | +89.7% | Reiterated | 12.10.26on TipRanks 17:45 | −7.5%next day +1.5% | ↗ |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $160 → $184+15.0% | Buy | +129.6% | Reiterated | 12.10.26on TipRanks 14:15 | +0.1%next day −7.5% | ↗ |
| Swayampakula Ramakanth★★★★★★★★★★#445 · hits 47% · avg +21.2% | H.C. Wainwright | $195 → $200+2.6% | Buy | +149.6% | Reiterated | 12.10.26on TipRanks 11:35 | +0.1%next day −7.5% | ↗ |
| Lisa Walter★★★★★★★★★★#5591 · hits 50% · avg +3.0% | RBC Capital | $135 → $155+14.8% | Buy | +93.4% | Reiterated | 08.10.26on TipRanks 09:05 | +1.3%next day +5.1% · 5 days +1.6% | ↗ |
| Brian Skorney★★★★★★★★★★#12116 · hits 37% · avg −5.6% | Robert W. Baird | $123 → $130+5.7% | Buy | +62.2% | Reiterated | 29.09.26on TipRanks 07:30 | −0.3%next day −2.1% · 5 days −11.4% | ↗ |
| Joseph Thome★★★★★★★★★★#320 · hits 57% · avg +24.8% | TD Cowen | $140 | Buy | +74.7% | Reiterated | 28.09.26on TipRanks Sep 29 01:15 | −1.2%next day −0.3% · 5 days −8.6% | ↗ |
| Joseph Schwartz★★★★★★★★★★#135 · hits 54% · avg +31.9% | Leerink Partners | $154 | Buy | +92.2% | Reiterated | 28.09.26on TipRanks Sep 29 00:55 | −1.2%next day −0.3% · 5 days −8.6% | ↗ |
| Jonathan Wolleben★★★★★★★★★★#249 · hits 53% · avg +23.6% | Citizens JMP | $146 → $137−6.2% | Buy | +71.0% | Reiterated | 06.08.26on TipRanks 05:55 | −10.9%next day +6.3% · 5 days +3.7% | ↗ |
| Joshua Schimmer★★★★★★★★★★#407 · hits 51% · avg +19.0% | Cantor Fitzgerald | $140 | Buy | +74.7% | Assigned | 05.08.26on TipRanks Aug 6 07:55 | +1.6%next day −10.9% · 5 days −6.8% | ↗ |
| Kalpit Patel★★★★★★★★★★#1436 · hits 39% · avg +16.1% | Wolfe Research | $145 | Buy | +80.9% | Initiated | 19.05.26on TipRanks 06:15 | +0.8%next day +0.3% · 5 days −0.5% | ↗ |
| Ryan Deschner★★★★★★★★★★#506 · hits 69% · avg +41.7% | Raymond James | $164 → $165+0.6% | Buy | +105.9% | Reiterated | 07.05.26on TipRanks 08:50 | −6.2%next day +3.3% · 5 days +6.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Mirum Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $146 at a price of $85.48 (+71.3%); now: $154 at $80.14 (+92.2%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 13 | 12 | 5 | 6 | 13 |
| Buy | 19 | 17 | 13 | 17 | 17 | 16 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 17.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.49 (from $-0.87 to $0.05). Last quarter: $-1.06.
Sales
Next quarter’s sales estimate — $178M (from $170M to $182M). Last quarter: $176M.
Best top-analyst consensus in the sector · Healthcare
About Mirum Pharmaceuticals
- CEO: Christopher Peetz
- Employees: 433
- 989 East Hillsdale Boulevard, Foster City, CA, 94404, US
- www.mirumpharma.com
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Data from the stock’s TipRanks forecast page, read 46 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗